Healthtech Startups
17,195 companies tagged Healthtech, with their investors and founders.
0 investors
0 investors
CEL-SCI Corporation is a biotech company developing immunotherapies, particularly Multikine, which is advancing through FDA regulatory processes. The company is focused on cancer treatment and has progressed to Phase 3 clinical trials.
0 investors
Celecor develops zalunfiban (Disaggpro), an investigational platelet inhibitor drug designed for rapid subcutaneous administration by first responders in pre-hospital treatment of STEMI heart attacks. The company focuses on acute cardiovascular care for patients experiencing the most severe form of heart attack.
0 investors
0 investors
0 investors
Cellectar Biosciences is a clinical-stage oncology company developing targeted cancer therapies using its proprietary PLE (phospholipid ether) delivery platform, which delivers therapeutic payloads directly to cancer cells. It focuses on advanced cancers with high unmet needs, including work related to triple-negative breast cancer.
0 investors
Cellective Biotherapy develops regulatory B10 cell-based immunotherapies designed to enhance or inhibit immune responses for treating cancers, autoimmunity, immunodeficiency, and infectious disease. Its pipeline focuses on first-in-class B cell-directed therapies.
0 investors
Cellens develops a non-invasive, urine-based cancer diagnostics platform (Octosense) that uses nanoscale atomic-force imaging of single-cell biophysical markers combined with machine learning to detect cancer, with early data focused on bladder cancer detection. It applies mechanobiology and label-free cell analysis to cancer screening.
0 investors
CellSolutions develops products for cytopathology sample preparation, cellular preservation and presentation, and digital automated screening with diagnostic interpretation. It serves clinical diagnostic applications, drawing on expertise in diagnostic cytopathology, clinical biochemistry, image analysis, and software engineering.
0 investors
Cellular Logistics develops biological products focused on cardiac treatments, combining expertise in cell therapy and cGMP manufacturing to advance novel therapies for heart failure and interventional cardiology applications.
0 investors
CellVax Therapeutics is a clinical-stage company developing personalized cell-based cancer immunotherapy that converts a patient's own tumor cells into antigen-presenting "Tumor Presenting Cells" to trigger a multi-neoantigen immune response. Its lead product, FK-PC101, targets high-risk prostate cancer patients after prostatectomy, with a platform intended to extend to other solid tumors.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors